PA5-16793

antibody from Invitrogen Antibodies

Targeting: SLC2A1 CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR

Provider product page for PA5-16793

Western blot

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [37]
Comments [0]
Validations
Western blot [1]
Immunohistochemistry [1]
Other assay [10]

Submit

Product number: PA5-16793 - Provider product page
Provider: Invitrogen Antibodies
Product name: GLUT1 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: PA5-16793 targets GLUT-1 in IHC (P), WB, and IF applications and shows reactivity with Human and Rat samples.
Concentration: 0.4 mg/mL

SLC2A1 protein structure - PA5-16793 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Imaging using IRDye800CW 2-DG and [ 18 F]FDG. ( a ) Sagittal view of the [ 18 F]FDG-PET signal of a xenografted mouse showing high activity at the site of the xenografted tumor (tumor volume of 775 mm 3 ). The arrow pinpoints the position of the tumor as identified by [ 18 F]FDG. ( b ) The fDOT IRDye800CW 2-DG signal at the corresponding sagittal plane. The area, in which the fDOT reconstruction is performed, is depicted by a dotted white frame . ( c ) Fused PET/fDOT sagittal image originating from the images of ( a ) and ( b ). ( d ) Sagittal view of the volumes occupied by the fDOT ( blue ) and PET ( red ) signal rendered to the 3D surface of the mouse ( gray ). ( e , f , and g ) The equivalents of ( a ), ( b ), and ( c ) are presented, but in the axial view; ( h ) Axial view of fused fDOT/CT image at the level of the tumor. ( i ) Immunohistochemical labeling for GLUT-1 expression ( in red ) in the excised tumor. Nuclei ( in blue ) are counterstained with DAPI. ( j ) Fluorescence image shows the biodistribution of IRDye800CW 2-DG signal in the same section than ( i ). ( k ) Image of the fusion of ( i ) and ( j ) shows the co-localization of the GLUT-1 and the IRDye800CW 2-DG. ( l ) White light image of the whole animal axial section.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 ACSL4 upregulation enhanced the stability of GLUT1 protein and reduced its ubiquitination. ( A ) After 12 hours of cell transfection with si-ACSL4 or OE-ACSL4, Huh-7 cells were treated with CHX (100 mug/mL) for 0, 1, 2, 4, 8 or 24 hours, and the western blotting assay was performed to detect GLUT1 expression. ( B ) An IP assay was used to detect the interaction between Ub and GLUT1 proteins after Huh-7 cells were transfected with si-ACSL4 or OE-ACSL4. ( C ) After 12 hours of cell transfection with si-ACSL4 or OE-ACSL4, SK-HEP-1 cells were treated with CHX (100 mug/mL) for 0, 1, 2, 4, 8 or 24 hours, and the western blotting assay was performed to detect GLUT1 expression. ( D ) IP assay was used to detect the interaction between Ub and GLUT1 protein in SK-HEP-1 cells. ( * P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Evaluation of the effects of the ACSL4/GLUT1 axis on cell proliferation, apoptosis and tumorigenesis in Huh-7 and SK-HEP-1 cells. ( A , B ) The mRNA and protein expression levels of GLUT1 were determined by RT-PCR and western blotting assays after cells were transfected with sh-GLUT1 or sh-NC, respectively ( * P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Evaluation of the levels of GLUT1 and O-GlcNAc in HCC and their clinical significance. ( A ) Immunohistochemistry technology was used to assess the protein levels of ACSL4, O-GlcNAc and GLUT1 in HCC tissues and adjacent normal tissues (Scale bar = 100 mum). ( B - D ) Pearson correlation analysis of the correlations between the levels of ACSL4, O-GlcNAc and GLUT1 in HCC tissues. ( E , F ) Kaplan-Meier analysis of the relationship between GLUT1/O-GlcNAc levels and the overall survival of patients with HCC.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Glut 1 and 4 expression ( A , C ) and protein levels ( B , D ) in placenta from normal ( CTRL ) and overweight ( OW ) women. ( A ) qPCR analysis of GLUT1 mRNA in normal ( n = 32) and overweight ( n = 26) placental tissue. ( B ) Representative WB (high panel) and corresponding densitometry (low panel) of GLUT1 in placenta from CTRL ( n = 12) and OW ( n = 18) women. ( C ) qPCR analysis of GLUT4 mRNA in normal ( n = 26) and overweight ( n = 25) placental tissue. ( D ) Representative WB (high panel) and corresponding densitometry (low panel) of GLUT4 in placenta from CTRL ( n = 12) and OW ( n = 18) women. Data are presented as mean +-ES.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 GLUT 1 and 4 expression ( A , C ) and protein levels ( B , D ) in placenta explants from normal ( CTRL ) and overweight ( OW ) women. ( A ) Fold Change of GLUT1 mRNA in normal ( n = 3) and overweight ( n = 5) placental explants. ( B ) Representative WB (left panel) and corresponding densitometry (right panel) of GLUT1 in placenta explants from CTRL ( n = 6) and OW ( n = 5) women. ( C ) Fold Change of GLUT4 mRNA in normal ( n = 3) and overweight ( n = 5) placental explants. ( D ) Representative WB (left panel) and corresponding densitometry (right panel) of GLUT4 in placenta explants from CTRL ( n = 6) and OW ( n = 5) women. Data are presented as mean +-ES. Significance was determined using an unpaired two-sided t -test. * p < 0.05.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 GLUT 1 and 4 expressions ( A , C ) and protein levels ( B , D ) in placenta explants treated with BPA from control pregnancy. ( A ) Fold Change of GLUT1 mRNA in placental explants from NW women ( n = 3) treated with BPA 1 nM and BPA 1 muM compared to the vehicle as control. ( B ) Representative WB (left panel) and corresponding densitometry (right panel) of GLUT1 in placental explants from NW women ( n = 4) treated with BPA 1 nM and BPA 1 muM compared to the vehicle as control. ( C ) Fold Change of GLUT4 mRNA in placental explants from NW women ( n = 3) treated with BPA 1 nM and BPA 1 muM compared to the vehicle as control. ( D ) Representative WB (left panel) and corresponding densitometry (right panel) of GLUT4 in placental explants from NW women ( n = 4) treated with BPA 1 nM and BPA 1 muM compared to the vehicle as control. Data are presented as mean +-ES. Significance was determined using a one-way ANOVA and Bonferroni's test for post hoc comparisons * p < 0.05. Ct: control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 GLUT 1 and 4 expressions ( A , C ) and protein levels ( B , D ) in placenta explants treated with BPA from overweight women. ( A ) Fold Change of GLUT1 mRNA in placental explants from OW women ( n = 5) treated with BPA 1 nM and BPA 1 muM compared to the vehicle as control. ( B ) Representative WB (left panel) and corresponding densitometry (right panel) of GLUT1 in placental explants from OW women ( n = 6) treated with BPA 1 nM and BPA 1 muM compared to the vehicle as control. ( C ) Fold Change of GLUT4 mRNA in placental explants from OW women ( n = 5) treated with BPA 1 nM and BPA 1 muM compared to the vehicle as control. ( D ) Representative WB (left panel) and corresponding densitometry (right panel) of GLUT4 in placental explants from OW women ( n = 6) treated with BPA 1 nM and BPA 1 muM compared to the vehicle as control. Data are presented as mean +-ES. Significance was determined using a one-way ANOVA and Bonferroni's test for post hoc comparisons * p < 0.05. Ct: control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 Functional and phenotypical characterization of presort- and GP2 + -derived aggregates. a Insulin secretion (ng insulin/mug DNA) from three different batches of aggregates generated from H1-derived presort and GP2 + cells at day 25, 24, and 22 of differentiation. N = 6 of 20-25 representative aggregates treated with low (2.8 mM) and high (16.7 mM) glucose and KCl (45 mM) for 45 min, error bars indicate s.e.m. b INSULIN (INS), NKX2-2, GLUT1 and MAFA immunostaining of unsorted (PRESORT) and GP2 + H1 cells at day 23 of differentiation. Scale bar represents 100 mum